General Information of Drug (ID: DMXY980)

Drug Name
VU0364770
Synonyms
61350-00-3; VU 0364770; VU0364770; N-(3-chlorophenyl)picolinamide; N-(3-chlorophenyl)-2-pyridinecarboxamide; N-(3-chlorophenyl)pyridine-2-carboxamide; CHEMBL556667; 2-Pyridinecarboxamide, N-(3-chlorophenyl)-; AC1LHD0L; GTPL6234; SCHEMBL2530324; cid_836002; KS-00001CNQ; CTK2E1861; DTXSID00356877; MolPort-002-826-420; ZINC362766; HMS3651P19; EX-A1099; BCP19097; s2862; 2565AH; BDBM50293743; AKOS003020541; CS-6072; KB-276111; HY-100588; VU-0364770; N-(3-chloro-phenyl)-pyridine-2-carboxamide; SW219537-1
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 232.66
Logarithm of the Partition Coefficient (xlogp) 2.6
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C12H9ClN2O
IUPAC Name
N-(3-chlorophenyl)pyridine-2-carboxamide
Canonical SMILES
C1=CC=NC(=C1)C(=O)NC2=CC(=CC=C2)Cl
InChI
InChI=1S/C12H9ClN2O/c13-9-4-3-5-10(8-9)15-12(16)11-6-1-2-7-14-11/h1-8H,(H,15,16)
InChIKey
SUYUTNCKIOLMAJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
836002
CAS Number
61350-00-3
TTD ID
D0W9VN

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metabotropic glutamate receptor 4 (mGluR4) TTICZ1O GRM4_HUMAN Modulator (allosteric modulator) [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6234).
2 The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2012 Feb;340(2):404-21.